Today: 9 June 2026
Vida CEO Steps In as $15 Million AI IPO Hits Reality Check
20 May 2026
2 mins read

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Austin, May 20, 2026, 08:05 (CDT)

  • Vida finished its $15 million IPO on May 18, putting 3.75 million Class A shares out at $4 apiece.
  • Lyle Pratt, the CEO, picked up 312,900 shares for roughly $1.19 million, according to a Form 4 filing.
  • The stock finished Tuesday at $2.29, far under its IPO price, ahead of Wednesday’s regular U.S. session.

Vida Global Inc. had a choppy start in public markets after its $15 million IPO. Shares fell well below the $4 offer price in early trading as buyers weighed the latest AI small-cap. Vida said it sold 3.75 million Class A common shares in the deal, its first pitch to public investors.

Vida is pitching a focused AI-agent story to public investors now, at a point when Wall Street is still funding artificial intelligence but looking less kindly on early-stage firms with little revenue, losses, and light volumes. Shares ended Tuesday at $2.29, down 42.8% from the IPO. Investing.com’s pre-market quotes showed the stock bouncing before the regular U.S. session.

Lyle Pratt, chief executive, picked up 312,900 shares for roughly $1.19 million, a Form 4 filed May 18 shows. According to the filing, Pratt bought 187,500 shares at $4 during the IPO and added two more open-market lots at average prices of $3.9547 and $3.1055.

Vida calls its product an “AI agent operating system.” The software lets users build, deploy and run agents that work across phone, text, email, and chat. The platform is used for things like phone reception, lead follow-up, routing support requests, updating CRM systems, and handling payments. Investing.com

Vida’s May 18 prospectus spells out how new the business is. The company showed revenue of $551,383 in 2025, up from $14,402 the year before. Net loss also widened, reaching $2.9 million from $742,478. Operating expenses jumped 165% to $3.4 million.

Vida said it plans to spend the roughly $12.5 million net IPO proceeds on working capital, operating expenses, partner enablement, engineering, customer success and automation. The company said it might also put some of the proceeds toward acquisitions or investments, but there are no binding agreements.

Underwriters led by The Benchmark Company have a 30-day window to buy as many as 562,500 additional Class A shares at the IPO price, excluding underwriting fees. VIDA said its shares started trading on NYSE American and NYSE Texas under the symbol VIDA on May 15.

Pratt said in February that firms want more than just separate AI tools, describing Vida as “a true operating system” that handles high volumes of AI interactions. He added that service firms could bundle omnichannel AI agents as managed offers, with pricing, branding, and monitoring controls. PR Newswire

Competitive threats aren’t distant. Vida, in its prospectus, listed Decagon, Synthflow and Vapi as AI-agent or developer-infrastructure firms it sees among its competitors. The filing also said bigger communications and contact-center firms can package AI tools at lower prices or sometimes for free.

The risk is clear. Vida said it has a short track record, is likely to keep losing money for now, and depends on sales led by partners. It also relies on third parties for large language models, phone systems, cloud and payments. Two customers made up 29.7% and 13.4% of its 2025 revenue. If pilots don’t convert to full rollout, or if customers pick bundled products from bigger firms, the added cash could just extend the runway, not drive growth.

Stock Market Today

  • Toast (TOST) Stock Down 29% YTD Amid Mixed Valuation Signals
    June 9, 2026, 9:43 AM EDT. Toast (TOST) shares have fallen 29.2% year to date, hitting $24.10 after a 16.6% slide over three months. Market debate centers on whether the current price undervalues Toast's growth prospects or reflects headwinds in hospitality tech. A popular valuation narrative pegs fair value at $33.96, citing demand for Toast's AI-driven restaurant tools amid labor shortages and expansion into new markets. This represents a 29% discount to current trading levels. However, risks remain, including high sales costs and margin pressure from competition and tariffs. Investors weigh steady revenue growth and margin improvement against these challenges as Toast navigates a turbulent period.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open
Previous Story

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

Carnival stock price drops more than 6% as oil tops $100, dragging CCL and CUK lower
Next Story

Carnival Shares Rise as Dividend Returns, Fuel Exposure in View

Go toTop